false 0001514183 0001514183 2025-03-04 2025-03-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 4, 2025

 

Silo Pharma, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   001-41512   27-3046338
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

677 N. Washington Boulevard

Sarasota, FL

   34236
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (718) 400-9031

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Rule 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock, par value $0.0001 per share   SILO   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 Other Events.

 

On March 4, 2025, the United States Patent and Trademark Office granted a patent (Patent No. US 12,239,614) for the Patent Application Serial No. 17/954864 exclusively licensed to Silo Pharma, Inc. from Columbia University and titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females.”

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

-1-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SILO PHARMA, INC.
     
Date: March 7, 2025 By: /s/ Eric Weisblum
    Eric Weisblum
    Chief Executive Officer

 

 

-2-

 

v3.25.0.1
Cover
Mar. 04, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 04, 2025
Entity File Number 001-41512
Entity Registrant Name Silo Pharma, Inc.
Entity Central Index Key 0001514183
Entity Tax Identification Number 27-3046338
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 677 N. Washington Boulevard
Entity Address, City or Town Sarasota
Entity Address, State or Province FL
Entity Address, Postal Zip Code 34236
City Area Code 718
Local Phone Number 400-9031
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol SILO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Silo Pharma (NASDAQ:SILO)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025 Plus de graphiques de la Bourse Silo Pharma
Silo Pharma (NASDAQ:SILO)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025 Plus de graphiques de la Bourse Silo Pharma